DOCSLIB.ORG

Biem Pharmaceuticals Is

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Company presentation 2017 vs. 2 Biem Pharmaceuticals is Pharmaceutical manufacturer with headquarters in Ankara Pharmaceutical marketing and distribution company Proprietary portfolio of high-value branded pharmaceutical products in Turkey Global presence advancing in more than 23 countries Committed to innovative solutions in Oncology, Hematology, Radiology, Ophthalmology, Neurology. To become the FIRST REMEDY for saving To achieve growth in our therapeutic field lives by increasing life quality with high with an innovative approach and steady tech, pioneering products and ONLY growth REMEDY able to provide drugs always focused to produce the best quality produced with innovative technology products, safe and efficient, by searching without pursuing high profit margins, for innovative solutions for happy and healthy illnesses that affects only a small lifes percentage of the population To increase the quality of our health services in all its activities, while preserving the ethical values of the health industry Biem as part of its strategy has accelerated its expansion activities and products portfolio with a big focus on registration sales, marketing and manufacturing on the domestic and international pharmaceutical market. Biem Function &Value Chain Distributor Supply Management & Chain/ Commercial CS Accounting Regional Representation Manufacturi Planning / Forecast & Biem ng through Demand CMOs Local Distribution, Regional Sales and Marketing Technical Regulatory Distributor Direct Local Distribution R&D Strong R&D team Regulatory, Technical & Consultancy Strong Regulatory Team, Market Assessment, Business Development Biem has key partnerships with leading Global Pharmaceutical companies: Active Sales Canada Azerbaijan Romania Russia Belarus Kuwait Chile Georgia Yemen Bosnia&H Kyrgzystan Albania Sri Lanka Moldova Vietnam India Sudan Costa Rica Tunisia Panama Myanmar Irak Makedonya Malaeysia Pakistan Yemen Domestic Market: International Market: Malaysia a steady growth in the therapeutic market is International business is increasing due to our expected due to our ongoing portfolio. overseas sales activity through product registration in more than 23 countries. Biem portfolio consists of 31 human products, of which: Others Radiocontrast %12 Imaging 12% Oncology 19.4% Opthalmology 30 % Transplantology 6% Intensive Care %12 Anti-Infectives %9 Key moments Others : 2012: launch of the Emaray and Pamiray Nephrology/Dialysis Nervous System 2014: launch of the Oncology and Ophthalmology Portfolio Anesthesia 2015: launch of the Intensive Care Portfolio Drug Name Active ingredient Treatment Area Launch date PAMIRAY® 300/370 Iopamidol CT Diagnostic imaging agent 50,100 ml 2012 BIEMEXOL® 300/350 50,100,200ml vials Iohexol CT Diagnostic imaging agent 2015 EMARAY® Gadopentetate Magnetic Resonance imaging 10,15,20 ml 2012 dimeglumine (MRI) GADODIEM ® Magnetic Resonance imaging 287 mg/ml in 10,15,20 ml Gadodiamide (MRI) 2015 CTI & MRI Market Potential Total Market Units Year Euro MRI 1,182,949.00 vials 22,789,012.00 Euro CTI 2,822,135.00 vials 31,444,105.00 Euro Units MAT/8/2017 IMS TENDER MARKET Rate (%) units 1.22 % 10.65 % T0 DIAGNOSTIC AGENTS 1,541,240 14,122,766.2 $ 53.77 % IOHEXOL 525,950 33.4 % OMNIPAQUE (Opakim) 525,950 33.4 % IOPROMIDE 506,176 32.1 % ULTRAVIST (Bayer) 506,176 32.1 % IOHEXOL 182,838 11.6 % BIEMEXOL (Biem) 182,838 32.06 % IOVERSOL 168,086 10.7 % OPTIRAY (Mallinckrodt) 168,086 10.7 % IOHEXOL 140.034 8.9 % KOPAQ (Onko) 140.034 IODIXANOL 18,213 1.2 % VISIPAQUE (Opakim) 18,213 1.2 % Iopamidol 10,516 1. IOHEXOL 2. IOPROMIDE 0.7 % PAMIRAY (BIEM) 10,526 3. IOVERSOL 4. IOPAMIDOL IOBITRIDOL 9,721 0.6 % 5. IODIXANOL 6. IOBITRIDOL XENETIX (Guerbet) 9,721 0.6 % 7. IOMEPROL IOMEPROL 8,692 0.6 % IOMERON (Santa Farma) 8,692 0.6 % IOPAMIDOL 2,653 0.2 % IOPAMIRO (Santa Farma 2,653 0.2 % Units TENDER MARKET MAT/8/2017 IMS Rate (%) 5.1 % 25.4 % Units 6.5 % T01E0 MRI AGENTS 452,441 6,758,845.15 $ GADOTERIC ACID 165,405 36,60% DOTAREM GUERBET 165,405 36,60% GADOPENTETIC ACID 85,406 18,90% MAGNEVIST BAYER 85,406 18,90% 11.5 % GADOBUTROL 71,803 15.90 % GADOVIST BAYER 71,803 15.90 % EMARAY 55,657 12,30% BIEM ILAC 55,657 12,30% GADODIAMIDE 26,122 5.80 % OMNISCAN OPAKIM 26,122 5.80 % GADOVERSETAMIDE 20,543 4,50% OPTIMARKCOVIDIEN 20,543 4,50% 13.8 % 1. GADOTERIC ACID GADOBENIC ACID 11,522 2,60% MULTIHANCE SANTA 2. GADOPENTETETIC ACID FARMA 11,522 2,60% 3. GADOBUTROL GADODIAMIDE 7,901 1,70% 4. GADODIAMIDE BIEM GADODIEM 7,901 1,70% 5. GADOVERSETAMIDE GADOXETIC ACID 7,204 1.6 % 6. GADOBENIC ACID PRIMOVIST BAYER 7,204 1.6 % 7. GADOXETIC ACID GADODIAMIDE 888 0.2 % Gadotu (Onko) 888 0.2 % Drug Name Active ingredient Treatment Area Launch date BUSLERA® Antineoplastic Agent / 6 mg / mL Busulfan conditioning treatment prior to 2014 conventional (HPCT) BEASTIN® Antineoplastics, Alkylating agent/Chronic Lymphocytic 25 mg, 100 mg Bendamustine HCl 2014 Leukemia, Non-Hodgkin Lymphoma OCLADRA ® Antineoplastics, Antimetabolite 10 mg / 5 mL Cladribine / Hairy Cell Leukemia 2014 VOTRON® Anti-vomiting and anti- 250 mcg / mL nausea/Chemotherapy side Palonosetron effects 2012 Busulfan Market Potential Total Market Units Year Euro Busulfan 12,294 Vials 812,048.00 Euro 3 % Units TENDER MARKET YTD/12/2016 Rate (%) (Absolute) BUSULFAN 12,294 52 % 45 % BUSLERA 6532 %52 6532 BIEM ILAC 6532 VIAL INF 60 MG 1 10 MG BUSILVEX 5498 %45 5498 IBRAHIM AMP INFUSION 6 MG 1 10 5498 ML MYLERAN 264 %3 1. Busilvex 2. Buslera 3. Myleran VLD DANISMANLIK 264 TABS 2 MG 100 264 Drug Name Active ingredient Treatment Area Launch date BIEMIB® Mantle cell Lymphoma, Non- 3.5 mg Bortezomib Hodgkin Lymphomai Multiple 2015 Myeloma LETROKS® Antineoplastic agent/Breast 2 mg, 5 mg Letrozol cancer 2009 Drug Name Active ingredient Treatment Area Launch date CALSIPAR ® Systemic Hormonal Preparations – Anti- 10 mcg / 2 Ml 5 mvg / mL Paricalcitol Parathyroid Agents / Its primary use in 2017 medicine is in the treatment EMFER® 100mg/5 ml ampoules Iron Sucrose Haematinics (iron supplements) 2014 BIEMPARIN® Heparine sodium Anticoagulant therapy 2016 4mg/4ml BIEMEFRIN® Norepinephrine Antihypotensives/Acute hypotension 2014 4mg/4ml ERBINNA® Omeprazole Sodium Proton Pump Inhibitors / Gastroesophageal 2017 40 mg Reflux Disease, Peptic Ulcer Disease and Zollinger-Ellison Syndrome. Drug Name Active ingredient Treatment Area Launch date MRSACIN® Tygecycline Antibiotic/Antibacterial for 2014 50mg systemic use TROZASIN ® Voriconazole Antifungal, Systemic/Invasive 2016 200 mg/ aspergillosis; Nonneutropenic candidemia; KOLISTATE® Colistimethate Sodium Anti-Infectives-Other 2017 150 mg Antibacterials / Selected Aerobic Gram-Negative Pathogens in Patients with Limited Treatment Options Drug Name Active ingredient Treatment Area Launch date SEDOZOLAM® Midazolam Anesthetic/Hypnotics/Sedativ 2017 5mg/5ml, 15mg/3ml e/Preoperative Sedation; LOKARIL® Lidocaine / Prilocaine Local Anesthetics / Dermal 2017 %5 Cream Anesthesia, Intravenous Catheter Insertion, Blood Sampling, Superficial Surgical Procedures and Topical Anaesthesia of Leg Ulcers for Cleansing or Debridement Drug Name Active ingredient Treatment Area Launch date PARGICYL ® 50 mg / 5 mL Nerbous System – Dopamine Apomorphine HCl Agonists / Parkinson’s Disease 2017 20 mg / 2 mL Drug Name Active ingredient Treatment Area Launch date ZARIDINEX ® Anti-infective quinolone 0,3% Ophthalmic antibiotics/bacterial eye Ofloxacine 2014 solution infection ENFLUAT® Nonsteroidal anti-inflammatory 0,4% Ophthalmic Ketorolac 2014 drug for ophthalmic use solution Tromethamine Future of BIEM Stage 1 R&D Center Stage 2 New Manufacturing Oncology Facility Thank you Address:Turgut Reis Cad. No:21 Tandoğan/Ankara Phone: (0312) 230 29 29 Fax: (0312) 230 68 00.
Recommended publications
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection

    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
  • Xx250 Spc 2015 Uk

    Xx250 Spc 2015 Uk

    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except

    01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except

    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Imaging Diagnostics by Combining Contrast Agents

    Imaging Diagnostics by Combining Contrast Agents

    (19) TZZ Z _T (11) EP 2 907 526 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.08.2015 Bulletin 2015/34 A61K 49/04 (2006.01) A61K 51/04 (2006.01) A61K 49/06 (2006.01) (21) Application number: 15155866.5 (22) Date of filing: 20.06.2008 (84) Designated Contracting States: (72) Inventor: Wiebelitz, Ulrike AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 13158 Berlin (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Kilger, Ute Boehmert & Boehmert (30) Priority: 22.06.2007 EP 07110922 Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte (62) Document number(s) of the earlier application(s) in Pettenkoferstrasse 20-22 accordance with Art. 76 EPC: 80336 München (DE) 12199299.4 / 2 572 735 12168380.9 / 2 514 442 Remarks: 08774183.1 / 2 170 405 This application was filed on 20-02-2015 as a divisional application to the application mentioned (71) Applicant: mivenion GmbH under INID code 62. 10115 Berlin (DE) (54) Imaging diagnostics by combining contrast agents (57) The present invention relates to the use of a combination of several contrast agents having different imaging properties with respect to imaging representation. EP 2 907 526 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 907 526 A1 2 Description from suspect lesions and to prepare and assess these samples histopathologically. [0001] The present invention relates to the use of a [0005] MRI examination of the female breast has very combination of several contrast agents having different high sensitivity in comparison to other imaging modali- imaging properties.
  • Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23

    Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23

    1 26 May 2016 2 EMA/CHMP/337820/2016 3 Committee for Medicinal Products for Human Use (CHMP) 4 Guideline on core SmPC and Package Leaflet for gadoteric 5 acid 6 Draft Draft agreed by Radiopharmaceutical Drafting Group April 2016 Adopted by CHMP for release for consultation 26 May 2016 Start of public consultation 1 June 2016 End of consultation (deadline for comments) 30 September 2016 7 Comments should be provided using this template. The completed comments form should be sent to [email protected]. 8 Keywords Magnetic resonance, contrast media, gadolinium compounds, core SmPC, core Package Leaflet, gadoteric acid 9 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 10 Guideline on core SmPC and Package Leaflet for gadoteric 11 acid 12 Table of contents 13 Executive summary ..................................................................................... 3 14 1. Introduction (background) ...................................................................... 3 15 2. Scope....................................................................................................... 3 16 3. Legal basis .............................................................................................. 3 17 4. Core SmPC and Package Leaflet for gadoteric acid .................................
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini

    Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini

    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
  • National Code Item Name 1

    National Code Item Name 1

    NATIONAL CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 800,000 02-01-00002 Digitoxin 100mcg Tablet 800,000 02-01-00003 Digoxin 125 mcg Tablet 800,000 02-01-00004 Digoxin 250 mcg Tablet 15,000,000 02-01-00005 Digoxin 50mcg /ml PG Elixir 800,000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800,000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800,000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50,000,000 02-01-00009 Bumetanide 1 mg Tablet 800,000 02-01-00010 Chlorthalidone 50mg Tablet 2,867,000 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800,000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 6,625,000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800,000 02-01-00014 Frusemide 40mg Tablet 20,000,000 02-01-00015 Frusemide 500mg Scored Tablet 800,000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800,000 02-01-00017 Frusemide 4mg/ml Oral Solution 800,000 02-01-00018 Frusemide 8mg/ml oral Solution 800,000 02-01-00019 Hydrochlorothiazide 25mg Tablet 800,000 02-01-00020 Hydrochlorothiazide 50mg Tablet 950,000 02-01-00021 Indapamide 2.5mg Tablet 800,000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800,000 02-01-00023 Spironolactone 25mg Tablet 7,902,000 02-01-00024 Spironolactone 100mg Tablet 11,451,000 02-01-00025 Xipamide 20mg Tablet 800,000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800,000 02-01-00027 Acebutolol 200mg Tablet 800,000 02-01-00028 Atenolol 100mg Tablet 120,000,000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 20,000,000 02-01-00030 Atenolol 25mg Tablet 1,483,000 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800,000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800,000 02-01-00033 Carvedilol 6.25mg Tablet 800,000 02-01-00034 Carvedilol 12.5mg Tablet 800,000 02-01-00035 Carvedilol 25mg Tablet 800,000 02-01-00036 Esmolol Hcl 10mg/ml I.V.
  • Page 1 Note: Within Nine Months from the Publication of the Mention

    Page 1 Note: Within Nine Months from the Publication of the Mention

    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
  • Chemical Modifications of Porous Shape Memory Polymers For

    Chemical Modifications of Porous Shape Memory Polymers For

    molecules Article Chemical Modifications of Porous Shape Memory Polymers for Enhanced X-ray and MRI Visibility Grace K. Fletcher 1, Landon D. Nash 2, Lance M. Graul 1, Lindy K. Jang 1, Scott M. Herting 1, Matthew D. Wilcox 1, Tyler J. Touchet 1, Ana Katarina Sweatt 1, Mary P. McDougall 1,3, Steven M. Wright 1,3 and Duncan J. Maitland 1,2,* 1 Texas A&M University Biomedical Engineering, Bizzell St, College Station, TX 77843, USA; gracekfl[email protected] (G.K.F.); [email protected] (L.M.G.); [email protected] (L.K.J.); [email protected] (S.M.H.); [email protected] (M.D.W.); [email protected] (T.J.T.); [email protected] (A.K.S.); [email protected] (M.P.M.); [email protected] (S.M.W.) 2 Shape Memory Medical Inc., Santa Clara, CA 95054, USA; [email protected] 3 Texas A&M University Electrical and Computer Engineering, Bizzell St, College Station, TX 77843, USA * Correspondence: [email protected] Academic Editor: Irina Savina Received: 31 August 2020; Accepted: 12 October 2020; Published: 13 October 2020 Abstract: The goal of this work was to develop a shape memory polymer (SMP) foam with visibility under both X-ray and magnetic resonance imaging (MRI) modalities. A porous polymeric material with these properties is desirable in medical device development for applications requiring thermoresponsive tissue scaffolds with clinical imaging capabilities. Dual modality visibility was achieved by chemically incorporating monomers with X-ray visible iodine-motifs and MRI visible monomers with gadolinium content. Physical and thermomechanical characterization showed the effect of increased gadopentetic acid (GPA) on shape memory behavior.